原发中枢神经系统淋巴瘤诊治进展
Advances in diagnosis,molecular pathogenesis and treatment of primary central nervous system lymphoma
陈弘韵 1张薇1
作者信息
- 1. 中国医学科学院北京协和医院血液科(北京,100730)
- 折叠
摘要
原发中枢神经系统淋巴瘤(primary central nervous system lymphoma,PCNSL)是一类罕见的侵袭性结外非霍奇淋巴瘤,具有独特的临床表现和生物学特征.基于大剂量甲氨蝶呤的系统化疗极大改善了该病的临床结局.然而,仍有部分患者对化疗耐药或最终出现复发.这些复发/难治性PCNSL患者对传统治疗反应欠佳,临床预后极差.因此,探寻新型疗法尤为重要.随着靶向药物、免疫治疗和细胞治疗的进展,如来那度胺、Bruton酪氨酸激酶抑制剂、嵌合抗原受体T细胞治疗越来越多地应用于PCNSL患者的治疗.
Abstract
Primary central nervous system lymphoma(PCNSL)is a rare,aggressive extra-nodal non-Hodgkin's lymphoma with unique clinical and biologic characteristics.The application of systemic chemotherapy based on high-dose methotrexate improves the clinical outcome.Nevertheless,a considerable fraction of patients are refractory to chemotherapies or undergo relapses eventually.The outcomes of these patients are dismal.More-over,the effect of traditional treatment for recurrent/refractory PCNSL patients is not satisfactory.Therefore,it is significant to explore new therapies.With the development of targeted agents,immunotherapies and cell thera-py,novel treatments including lenalidomide,Bruton's tyrosine kinase inhibitors,chimeric antigen receptor T-cell therapy are being attempted in PCNSL patients.
关键词
原发中枢神经系统淋巴瘤/来那度胺/BTK抑制剂/CAR-T细胞治疗Key words
primary central nervous system lymphoma/lenalidomide/BTK inhibitors/CART therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据